WinstonWınston
Back
Avita Medical logo

Avita Medical

RCEL
Medical - Devices · Healthcare
Price
$10.06
-0.03 (-0.30%)
Market Cap
$249.9M
Exchange
NASDAQ
Winston Score
Winston looking sleepy
No score yet — Winston is napping.
We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+14.4% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 24.4M (2021) → 27.9M (2025)

Winston Score History

The full picture

Avita Medical is a medical device company that makes a skin regeneration system called RECELL. The RECELL system lets doctors take a small patch of a patient's own skin and turn it into a spray that can cover large burn wounds. The main customers are hospitals and burn centers, primarily in the United States.

Avita makes money by selling the RECELL device and the single-use kits that go with each procedure — a classic razor-and-blades model. The company operates mainly in the US, with some international presence, and its gross margins are strong at over 80%, reflecting the high value of its proprietary technology. However, Avita is still losing money at the operating level, spending heavily on sales, marketing, and expanding RECELL's approved uses beyond burns into areas like soft tissue repair and vitiligo — and whether those new indications gain traction with surgeons will be the key factor in determining if the company can reach profitability.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+17.8% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

+34.2% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$21M/ year

Flat (+2% vs prior year)

29.1% of revenue

1.6x the sector average (18%)

Steady R&D investment year-over-year

Insider Activity

3.8%ownership

Flat

Insider ownership roughly steady over the past year

Cash Runway

~2 months

$11M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Avita Medical has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
81.9%
Premium pricing power — 81.9% gross margin
Profit after running costs
Operating Margin
-31.6%
Losing money on operations — -31.6%
Return on the money invested
ROCE
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+1.0%
Nearly flat sales (+1.0% YoY)
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
5/8 quarters
Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
Data not available
Spare cash per sale
FCF Margin
-49.1%
Burning cash (-49.1%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
N/A
Data not available
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial